首页 › 非小细胞肺癌 › 堪萨斯州 › Kansas City
Kansas City KS 非小细胞肺癌临床试验
11项针对 非小细胞肺癌的研究正在 Kansas City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
招募中1 期
- University of Kansas Medical Center, Kansas City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
招募中3 期
- University of Kansas Cancer Center, Kansas City
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- The University of Kansas Cancer Center, Kansas City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- The University of Kansas Hospital, Kansas City
- The University of Kansas Medical Center Medical Office Building, Kansas City
- University of Kansas Hospital Cambridge North Tower A, Kansas City
- 以及另外 1 项
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- University of Kansas Cancer Center, Kansas City
- Veteran Administration Eastern Kansas Healthcare, Leavenworth · 距离 21 英里
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
招募中1/2 期
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
招募中观察性研究
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
招募中观察性研究
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Kansas City的其他研究
- 心血管疾病14 项研究
- 心力衰竭13 项研究
- 肥胖症13 项研究
- 间质性肺病13 项研究
- 囊性纤维化13 项研究
- 乳腺癌12 项研究
- 膀胱癌12 项研究
- 急性髓系白血病12 项研究
- 前列腺癌12 项研究
- 肺癌11 项研究
- 慢性阻塞性肺病9 项研究
- 哮喘8 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。